Acumen Pharmaceuticals (ABOS) Retained Earnings (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Retained Earnings data on file, last reported at -$467.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 32.01% year-over-year to -$467.2 million; the trailing twelve-month figure through Mar 2026 stood at -$467.2 million (down 32.01% YoY), and the FY2025 full-year result was -$446.5 million, down 930108.33% from the prior year.
• Retained Earnings slipped to -$467.2 million in Q1 2026, from -$446.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $354.3 million in Q2 2022 to a low of -$467.2 million in Q1 2026.
• A 5-year average of -$161.2 million and a median of -$181.7 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings surged 407.26% in 2022 and plunged 930108.33% in 2025, its largest moves.
• Tracing ABOS's Retained Earnings over 5 years: stood at -$751000.0 in 2022, then sank by 29567.11% to -$222.8 million in 2023, then soared by 99.98% to -$48000.0 in 2024, then sank by 930108.33% to -$446.5 million in 2025, then slipped by 4.64% to -$467.2 million in 2026.
• Business Quant data shows ABOS's Retained Earnings at -$467.2 million in Q1 2026, -$446.5 million in Q4 2025, and $109000.0 in Q3 2025.